Year: 2024

Sampo plc’s share buybacks 28 October 2024

Written by Customer Service on October 29, 2024. Posted in Public Companies.

Sampo plc, stock exchange release, 29 October 2024 at 8:30 am EET Sampo plc’s share buybacks 28 October 2024 On 28 October 2024, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows: Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code) 2,620 40.85 AQEU 36,239 40.86 CEUX 762 40.92 TQEX 52,631 40.89 XHELTOTAL 92,252 40.88 *rounded to two decimals On 17 June 2024, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. On 16 September 2024, the Board of Directors of...

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine

Written by Customer Service on October 29, 2024. Posted in Public Companies.

Clinical study in children 2-11 years of age follows the recent EMA and WHO approvals of the MVA-BN mpox vaccine for adolescents 12-17 of age.COPENHAGEN, Denmark, October 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN® mpox/smallpox vaccine in children 2 to 11 years of age. The first children have now been vaccinated in the study, which is currently enrolling in the Democratic Republic of Congo (DRC) with plans also to include sites in Uganda. A total of 460 individuals are expected to participate in the study, which will compare the safety and immunogenicity of the vaccine between children aged 2 to 11 years of age to adults. The study (NCT06549530) is partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI). Results from this study could support an...

Press release – SPIE signs an agreement for the acquisition of Elektromontaż-Poznań

Written by Customer Service on October 29, 2024. Posted in Mergers And Acquisitions.

Cergy, October 29th, 2024 – SPIE, the independent European leader in multi-technical services in the areas of energy and communications, announces the signature of an agreement to acquire 100% of Elektromontaż-Poznań S.A. With nearly 75 years of experience, Elektromontaż-Poznań S.A. is specialized in electrical installation services including design, consulting, delivery and installation for customers from the industrial, commercial and public administration sectors in Poland. Elektromontaż-Poznań S.A. generated a revenue of c. € 70 million in 2023 and employs approximately 330 employees. With this acquisition, SPIE will strengthen its market share in the electrical and mechanical building technology sectors in Poland, while also expanding its portfolio of competencies and enlarging its customer base. Pawel Skowroński, Managing Director...

Aspo Group’s Interim Report, January 1 – September 30, 2024

Written by Customer Service on October 29, 2024. Posted in Earnings Releases And Operating Results.

Aspo Plc Interim report October 29, 2024, at 8:15 am Aspo Group’s Interim Report, January 1 – September 30, 2024 Successful strategy execution and profitability improvement continued Figures from the corresponding period in 2023 are presented in brackets. July–September 2024Net sales from continuing operations increased to EUR 146.6 (130.1) million Comparable EBITA from continuing operations was EUR 8.7 (7.7) million, 5.9% (5.9%) of net sales. The comparable EBITA of ESL Shipping was EUR 3.8 (4.1) million, Telko EUR 4.6 (3.2) million, and Leipurin EUR 1.3 (1.4) million EBITA from continuing operations was EUR 9.2 (8.4) million. EBITA of ESL Shipping was EUR 3.8 (4.1) million, Telko EUR 4.6 (3.2) million, and Leipurin EUR 1.3 (2.1) million Comparable ROE from continuing operations was 6.6% (13.1%) Comparable earnings per...

Aspo’s Board of Directors drives the company’s strategic growth and shareholders’ long-term value creation and decided not to make an additional distribution of funds to shareholders in 2024

Written by Customer Service on October 29, 2024. Posted in Public Companies.

Aspo PlcStock Exchange ReleaseOctober 29, 2024, at 8.00 am Aspo’s Board of Directors drives the company’s strategic growth and shareholders’ long-term value creation and decided not to make an additional distribution of funds to shareholders in 2024 Aspo has gone through a major transformation during the past three years. In practice the transformation includes a full exit from Russia and in parallel major growth investments in west, fully compensating for the lost revenue and profitability in east. As a reflection of this major transformation, the reported earnings per share (EPS) in 2023 was EUR -0.01 per share and the comparable EPS in 2023 was EUR 0.46 per share. The Annual General Meeting (AGM) held on April 12, 2024, approved a dividend distribution of EUR 0.24 per share and the dividend was paid on April 23, 2024. Furthermore,...

Corbion reports sales growth, profit improvement, and positive free cash flow driven by strong Q3 and upgrades full year guidance

Written by Customer Service on October 29, 2024. Posted in Public Companies.

Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through application of science, today publishes its results for the first nine months of 2023. Key highlights first nine months 2024:Organic sales growth: +2.6% (Q3: +9.2%):Volume/mix: +6.1% (Q3: +11.1%) Price: -3.5% (Q3: -1.9%)Continued Operations:Sales € 972.9 million (Q3: € 335.8 million) Adjusted EBITDA € 135.7 million (Q3: € 49.6 million) Operating profit € 62.1 million (Q3: € 28.5 million)Free Cash Flow € 302.1 million, € 50.8 million when excluding divestment proceeds Continued double digit growth in sales and Adjusted EBITDA in Health & Nutrition Continued positive volume/mix development in Functional...

Clariant delivers resilient Q3 profitability in a continued challenging market environment

Written by Customer Service on October 29, 2024. Posted in Public Companies.

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LRTHIRD QUARTER/NINE MONTHS | 2024Q3 2024 sales decreased by 1 % in local currency1 to CHF 991 million, with stable pricing and volume growth in Adsorbents & Additives and Care Chemicals offsetting lower Catalysts volumes Lucas Meyer Cosmetics delivered strong growth and 2 % of Group sales; integration well on track Q3 2024 EBITDA margin before exceptional items of 15.6 % versus 15.9 % in Q3 2023, reflecting lower sales partly offset by effective margin management Q3 2024 reported EBITDA margin of 14.0 % below 15.4 % in Q3 2023 due to lower Catalysts volumes and restructuring charges relating to corporate cost measures 9M 2024 sales decreased by 5 % in local currency to CHF 3.061 billion while the reported EBITDA margin improved to 15.6 % compared to 15.1 % in the prior year Outlook...

Notice on Public Offering of Subordinated Bonds of LHV Group

Written by Customer Service on October 29, 2024. Posted in Public Companies.

AS LHV Group (hereinafter LHV) hereby announces a public offering of LHV’s subordinated bonds. The offering is conducted on the basis of the prospectus affirmed by the Estonian Financial Supervision and Resolution Authority (FSA) on 28 October 2024, that has been disclosed on the date of this announcement on the web pages of LHV and the FSA. The public offering of the subordinated bonds will be carried out in Estonia, Latvia and Lithuania. This is the second issue of subordinated bonds, in the amount of up to EUR 20 million, under the bond programme confirmed in 2023. Under the bond programme EUR 35 million worth of subordinated bonds have previously been issued and altogether it is possible to raise up to EUR 200 million. Main Terms of Offering LHV offers publicly up to 20,000 subordinated bonds of LHV „EUR 6.00 LHV Group subordinated...

Idorsia announces financial results for the first nine months of 2024

Written by Customer Service on October 29, 2024. Posted in Public Companies.

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024. HighlightsNet revenue 9M 2024 at CHF 53 million. US GAAP operating loss 9M 2024 of CHF 154 million and Non-GAAP operating loss of CHF 248 million. Improved Guidance for 2024, driven by diligent cost control. QUVIVIQ™ (daridorexant) total net sales of CHF 39 million in 9M 2024. Commercial partnership for QUVIVIQ with Menarini France. QUVIVIQ approved for the treatment of insomnia in Japan. TRYVIO™ (aprocitentan) commercially available in the US since October 2024. JERAYGO™ (aprocitentan) approved by the European Commission in June 2024 and marketing authorization applications submitted in the UK, Canada, and Switzerland. Collaboration...

Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance

Written by Customer Service on October 29, 2024. Posted in Public Companies.

Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +10% (cc1, +9% USD) with core operating income up +20% (cc, +17% USD)Sales growth driven by continued strong performance from Entresto (+26% cc), Cosentyx (+28% cc), Kisqali (+43% cc), Kesimpta (+28% cc), Pluvicto (+50% cc) and Leqvio (+119% cc) Core operating income margin 40.1%, +340 basis points (cc), mainly driven by higher net salesQ3 operating income grew +123% (cc, +106% USD); net income up +121% (cc, +111% USD) Q3 core EPS grew +20% (cc, +18% USD) to USD 2.06 Q3 free cash flow1 of USD 6.0 billion (+18% USD) driven by higher net cash flows from operating activities Strong nine months performance with sales up +11% (cc, +9% USD) and core operating income up +20% (cc, +17% USD) Q3 selected innovation milestones:Kisqali FDA approval and positive CHMP opinion for...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals